Tag archives: PMPRB

Drug pricing: PMPRB releases scoping paper to consult on new Guidelines

Photo of Christopher A. GuerreiroPhoto of Kristin WallBy Christopher A. Guerreiro and Kristin Wall on Posted in Pharmaceuticals and life sciences
The Patented Medicine Prices Review Board (PMPRB) has released a scoping paper on themes and questions to develop new price review Guidelines. The scoping paper also includes information on how stakeholders can participate in the consultation. The deadline for written submissions addressing the scoping paper is December 20, 2023. Background The PMPRB has not had a … Continue reading

Drug pricing: PMPRB announces framework for new guidelines consultation

Photo of Christopher A. GuerreiroPhoto of Kristin WallBy Christopher A. Guerreiro and Kristin Wall on Posted in Pharmaceuticals and life sciences
The Patented Medicine Prices Review Board (PMPRB) has announced a framework for the launch of its consultation on new guidelines, beginning with a scoping paper to be published in advance of Policy Roundtable sessions to be held December 5 (English) and December 6 (French), 2023. The PMPRB has not had a full set of guidelines … Continue reading

Drug pricing: PMPRB finalizes Interim Guidance amendments

Photo of Christopher A. GuerreiroPhoto of Kristin WallBy Christopher A. Guerreiro and Kristin Wall on Posted in Life sciences and healthcare, Pharmaceuticals and life sciences
The Patented Medicine Prices Review Board (PMPRB) has amended its Interim Guidance to address prices of “New Medicines”, implementing a review threshold based on “below the median” of the PMPRB11 countries (Median International Price, MIP). “New Medicines” are defined as patented medicines that did not receive a PMPRB ceiling price as of July 1, 2022. … Continue reading

PMPRB Update: Federal Standing Committee on Health begins review of the Board

Photo of Christopher A. GuerreiroPhoto of Kristin WallBy Christopher A. Guerreiro and Kristin Wall on Posted in Life sciences and healthcare, Pharmaceuticals and life sciences
The Standing Committee on Health (HESA) has begun a study on the Patented Medicine Prices Review Board (PMPRB). HESA is made up of 12 Members of Parliament representing the four main parties in the House of Commons. In connection with this study, HESA has conducted two meetings to ask questions of witnesses regarding the PMPRB: The events … Continue reading

PMPRB excessive price decision quashed by Federal Court of Appeal

Photo of Christopher A. GuerreiroPhoto of Kristin WallBy Christopher A. Guerreiro and Kristin Wall on Posted in Intellectual property, Life sciences and healthcare, Pharmaceuticals and life sciences
The Federal Court of Appeal has quashed an excessive-price decision of the Patented Medicine Prices Review Board (PMPRB) in a proceeding concerning the drug SOLIRIS. The matter has been remitted to the PMPRB for redetermination. Procedural background The PMPRB issued a decision in 2017 finding that Alexion Pharmaceuticals Inc. sold SOLIRIS (eculizumab) at an excessive … Continue reading
LexBlog